News Stories

Novartis received FDA approval for a label update that will allow for use of Leqvio ^® (inclisiran) in certain patients at high risk of cardiovascular (CV) disease. This broader population allows for earlier Leqvio treatment in patients with elevated low-density lipoprotein cholesterol (LDL-C) and CV risk factors, such as diabetes and hypertension, who are at increased risk of atherosclerotic cardiovascular disease (ASCVD), beyond the previously approved ASCVD and heterozygous familial hypercholesterolemia (HeFH) patient population.

LEVERAGING IMPLEMENTATION SCIENCE 

Are you excited for a new year with the NLA? While we still have so much to accomplish in 2022, there is a lot of excitement about what we will be doing as we head into 2023. The NLA has developed a series of educational activities and engagement opportunities for our members and those interested in lipid management near and far, and we cannot wait for you to take advantage of all the offerings! Here are some of the plans for 2023: